[Present status of the multidisciplinary treatment of acute leukemia].
Recently marked progress in many fields around the treatment of acute leukemia has resulted a marked improvement in the therapeutic results. Establishment of fundamental principles of therapy, i.e., understanding of remission induction, consolidation and maintenance has supported a systemic analysis of treatment. New antileukemia drugs such as Aclacinomycin, THP-adriamycin, Epirubicin, Mitoxantrone, Vindesine, Etoposide, PL-AC together with the immunotherapeutic agent i.e., Bestatin, kurestin and Nocardia-CWS were studied and found to show their merits in the treatment. Monitoring the patients by 5000 leukocyte differential or the development of new antibiotics or improvement of laminar air flow rooms etc, has supported the antileukemic therapy. Bone marrow transplantation, allogeneic, syngeneic or autologous, has shown a very rapid progress and is proved to be a reliable treatment with very high rate of complete cure.
D015250:Aclarubicin / Q000031:analogs & derivatives*; D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D009279:Naphthacenes / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
D009279:Naphthacenes; C011157:aclacinomycins; D014750:Vincristine; D015250:Aclarubicin; D004317:Doxorubicin; C027260:pirarubicin; D014751:Vindesine